SCHEMBL3284338

SCHEMBL3284338

CC(Nc1nc(Nc2ccc(Cl)c(Cl)c2)ncc1C(F)(F)F)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 11/20 0.52
GSK3A P49840 1/20 0.49
GSK3B P49841 1/20 0.49
EGFR P00533 1/20 0.48
AURKA O14965 1/20 0.47
ULK1 O75385 1/20 0.47
KIT P10721 1/20 0.47
FLT3 P36888 1/20 0.47
SYK P43405 1/20 0.47
CDK1 P06493 2/20 0.46
CCNT1 O60563 1/20 0.46
CCNT2 O60583 1/20 0.46
CCNB2 O95067 1/20 0.46
CDK4 P11802 1/20 0.46
CCNB1 P14635 1/20 0.46
CCND1 P24385 1/20 0.46
CDK2 P24941 1/20 0.46
CDK7 P50613 1/20 0.46
CDK9 P50750 1/20 0.46
CCNB3 Q8WWL7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1916072 0.87 PTK2 (0.50) PTK2GSK3AGSK3BEGFRAURKA
SCHEMBL3284730 0.87 PTK2 (0.50) PTK2GSK3AGSK3BEGFRAURKA
SCHEMBL1917660 0.86 GSK3A (0.53) PTK2GSK3AGSK3BEGFRAURKA
SCHEMBL1918171 0.86 PTK2 (0.49) PTK2GSK3AGSK3BEGFRAURKA
SCHEMBL3291460 0.86 PTK2 (0.49) PTK2GSK3AGSK3BEGFRAURKA
SCHEMBL1918301 0.85 PTK2 (0.49) PTK2GSK3AGSK3BEGFRAURKA
SCHEMBL3288637 0.85 PTK2 (0.52) PTK2GSK3AGSK3BEGFRAURKA
SCHEMBL3292042 0.84 PTK2 (0.48) PTK2EGFRAURKAULK1SYK
SCHEMBL1916914 0.84 GSK3A (0.51) PTK2GSK3AGSK3BEGFRAURKA
SCHEMBL3286465 0.83 PTK2 (0.47) PTK2GSK3AGSK3BEGFRAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420630-B2 Pyrimidine derivatives BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2013-04-16 US disclosed
US-20100152167-A1 PYRIMIDINE DERIVATIVES BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-06-17 US disclosed
US-7709480-B2 Pyrimidine derivatives BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-05-04 US disclosed
US-7173028-B2 Pyrimidine derivatives BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-02-06 US disclosed
US-20060100211-A1 Pyrimidine derivatives BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-05-11 US disclosed
US-20030171359-A1 Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100211-A1 Pyrimidine derivatives TYMP, TYMS, DPYD PTK2 3366/4885GSK3A 1259/4885GSK3B 1036/4885
US-20030171359-A1 Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases COL1A1, MKI67, INSR PTK2 1110/4885GSK3A 1044/4885GSK3B 852/4885
US-20100152167-A1 PYRIMIDINE DERIVATIVES TYMP, TYMS, DPYD PTK2 3366/4885GSK3A 1259/4885GSK3B 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.